Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Triple-negative breast cancer with brain metastasis (TNBC-BM) has limited therapeutic strategies.
• Current immunotherapies, like monoclonal antibodies, face challenges crossing the blood-brain barrier (BBB).
• The BBB restricts the entry of large molecules, hindering effective brain metastasis treatment.

Purpose of the Study:

• To review naturally-derived molecules for potential immunotherapy against TNBC-BM.
• To explore molecules capable of blocking the PD-1/PD-L1 pathway.
• To assess the theoretical potential of these natural compounds for crossing the BBB.

Main Methods:

• Literature review of naturally-derived molecules.
• Analysis of molecules targeting the PD-1/PD-L1 interaction.
• Evaluation of physicochemical properties and pharmacokinetics for BBB penetration.

Main Results:

• Several natural compounds exhibit potential for PD-1/PD-L1 pathway inhibition.
• Discussion of mechanisms of action, physicochemical properties, and pharmacokinetics.
• Theoretical assessment of BBB traversal capabilities for selected natural molecules.

Conclusions:

• Naturally-derived molecules offer a promising avenue for TNBC-BM immunotherapy.
• These compounds may overcome BBB limitations, unlike traditional antibodies.
• Further research into these natural molecules could lead to novel treatments for brain metastasis.